Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Characteristics and Treatment Duration of Mavacamten Obstructive HCM Patient Support Program in Canada: A Retrospective Cohort Study

NCT06549608 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06549608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06549608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Characteristics and Treatment Duration of Mavacamten Obstructive HCM Patient Support Program in Canada: A Retrospective Cohort Study
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
April 20, 2024
Completion date
April 18, 2025
Enrollment
683 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertrophic cardiomyopathy